
Sign up to save your podcasts
Or


Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference. Together, they explore the latest data on Retatrutide's potential to deliver bariatric surgery-level weight loss, improve cardiometabolic health, and reshape the future of obesity and type 2 diabetes treatment.
otplinks.com
By Dave Knapp GLP-1 Industry Insider4.9
351351 ratings
Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference. Together, they explore the latest data on Retatrutide's potential to deliver bariatric surgery-level weight loss, improve cardiometabolic health, and reshape the future of obesity and type 2 diabetes treatment.
otplinks.com

336 Listeners

142 Listeners

67 Listeners

129 Listeners

1,680 Listeners

425 Listeners

264 Listeners

230 Listeners

33 Listeners

119 Listeners

162 Listeners

42 Listeners

178 Listeners

42 Listeners

22 Listeners